Abstract: eNOS is expressed in cardiac myocytes and plays an important role in cardiac contractile function. This study was designed to determine whether ex vivo eNOS gene transfer in ventricular myocytes affects cardiac contractile function. Replication-incompetent adenoviral vectors encoding eNOS or marker gene ␤-galactosidase (LacZ) were transduced into adult rat ventricular myocytes at an MOI of 10, 50, or 100 for 36 hours. Mechanical and intracellular Ca 2+ properties of myocytes were evaluated by video-based edge detection and fura-2 fluorescence. NOS protein expression and activity were assessed by Western blot and 3 H-arginine to 3 H-citrulline assay. Myocytes transduced with eNOS but not LacZ displayed enhanced eNOS but not iNOS expression associated with elevated NOS activity. Myocytes transduced with eNOS exhibited significantly elevated peak shortening and velocity of shortening/relengthening associated with enhanced basal as well as electrically stimulated rise of intracellular Ca 2+ compared with control or LacZ groups. The durations of shortening and relengthening were comparable in all groups. The eNOSinduced mechanical effects were paralleled with elevated phosphorylation of Akt. Furthermore, the phosphatidylinositol-3 (PI-3) kinase inhibitors wortmannin and LY294002 prevented eNOS-induced mechanical effects. These results revealed that gene transfer of eNOS directly promotes cardiomyocyte contractile function and intracellular Ca 2+ handling, suggesting therapeutic potential of eNOS gene transfer.
portant role in cardiac contractile function. This study was designed to determine whether ex vivo eNOS gene transfer in ventricular myocytes affects cardiac contractile function. Replication-incompetent adenoviral vectors encoding eNOS or marker gene ␤-galactosidase (LacZ) were transduced into adult rat ventricular myocytes at an MOI of 10, 50, or 100 for 36 hours. Mechanical and intracellular Ca 2+ properties of myocytes were evaluated by video-based edge detection and fura-2 fluorescence. NOS protein expression and activity were assessed by Western blot and 3 H-arginine to 3 H-citrulline assay. Myocytes transduced with eNOS but not LacZ displayed enhanced eNOS but not iNOS expression associated with elevated NOS activity. Myocytes transduced with eNOS exhibited significantly elevated peak shortening and velocity of shortening/relengthening associated with enhanced basal as well as electrically stimulated rise of intracellular Ca 2+ compared with control or LacZ groups. The durations of shortening and relengthening were comparable in all groups. The eNOSinduced mechanical effects were paralleled with elevated phosphorylation of Akt. Furthermore, the phosphatidylinositol-3 (PI-3) kinase inhibitors wortmannin and LY294002 prevented eNOS-induced mechanical effects. These results revealed that gene transfer of eNOS directly promotes cardiomyocyte contractile function and intracellular Ca 2+ handling, suggesting therapeutic potential of eNOS gene transfer. N itric oxide (NO) produced by the endothelial NO synthase (eNOS or NOS3) is an important determinant of regional blood flow, vascular remodeling, angiogenesis, and blood pressure. 1 In addition, NO has been shown to regulate a great variety of cardiac function, not only under normal conditions but also in ischemic and nonischemic heart failure, septic cardiomyopathy, cardiac allograft rejection, and myocarditis, independent of its vascular response. 2, 3 NO has been demonstrated to regulate ␤-adrenergic inotropic responsiveness, diastolic relaxation, ventricular remodeling, myocyte survival, and oxygen consumption. 2, 5 The concept of the physiological regulation of cardiac function by NO stemmed mainly from myocardial performance in response to NO donors or NOS inhibitors and, more recently, in genetically eNOS-deficient mice. 4, 6 Nevertheless, numerous experimental and clinical studies have yielded apparently conflicting results on the inotropic effect of NO from either endogenous or pharmacological sources. While some studies reported a negative inotropic effect of NO, 4, 7, 8 others did not. 4, 9, 10 Such discrepancies may be contributed by offsetting cardiac effects of NO on L-type Ca 2+ channels and sarcoplasmic reticulum (SR) Ca 2+ release 11 or by differences in species and experimental conditions such as the existence of heterogeneous cell types including nerve endings and fibroblasts since most of these studies were performed on multicellular preparations. In addition, it has been suggested that NO may exert different or even opposite cardiac inotropic effects under normal or pathologic (eg, heart failure) conditions. 11, 12 Changes in NO levels or myocyte sensitivity to NO appear to be associated with specific cardiac disorders such as diabetic or hypertrophic cardiomyopathies. 13, 14 Furthermore, alteration in myocardial eNOS expression often accompanies the onset of heart failure due to multiple etiologies. 15 These observations have validated the significance of eNOS in the regulation of cardiac contractile function. However, direct action of endogenous eNOS activation on the fundamental contractile unit, cardiac myocytes, has not been defined. Levels of NO achieved by exogenously added NO donors may not be physiological and thus may confound our understanding of the physiological action of NO in cardiac myocytes. In this study, we used the replicationdeficient recombinant adenovirus encoding eNOS to enhance NOS activity endogenously and examine the cardiac contractile response in isolated cardiac myocytes. Adenovirus has been considered one of the top choices among the viral vectors currently used for gene transfer, providing high capability of infecting a variety of differentiated cell types including cardiac myocytes. 16, 17 Isolated ventricular myocytes from adult rats were transfected with adenovirus vectors encoding either eNOS or marker gene ␤-galactosidase (␤-Gal or LacZ) ex vivo. Cardiac mechanical function, intracellular Ca 2+ homeostasis, and expression of key NO regulating molecule protein kinase B (PKB)/Akt were evaluated. 
MATERIALS AND METHODS

Cell Isolation Procedures
Recombinant eNOS Ex Vivo Gene Transfer to Cardiac Myocytes
To transfer and express recombinant eNOS gene into ventricular myocytes, replication-deficient adenoviral vectors encoding eNOS cDNA driven by a cytomegalovirus immediate early promoter (CMV) was used. The propagation, purification, and titration of the vectors were performed as described. 16 Adenoviral vector encoding a marker gene, ␤-galactosidase (␤-Gal or LacZ), was used in parallel with eNOS gene as a control vector. Isolated ventricular myocytes were transduced with adenoviral vectors (eNOS or LacZ, 10 8 -10 10 pfu/ml) in minimal essential medium (MEM) for 36 hours at 37°C. Non-transduced cells served as control. 16 We tested the relationship between adenoviral incubation duration and eNOS gene transfer efficacy and found that 36 hours of incubation time seemed to provide the optimal gene transfer efficiency without significantly affecting the myocyte mechanics. Our earlier study using the same experimental setting indicated that ventricular myocyte contractile function (such as myocyte shortening amplitude) remained stable between 12 and 48 hours of incubation; however, it started to deteriorate rapidly after 48 hours.
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Cell Shortening/Relengthening
Mechanical properties of ventricular myocytes were assessed using an IonOptix MyoCam® system (IonOptix Corporation, Milton, MA). 18 In brief, cells were placed in a Warner chamber mounted on the stage of an inverted microscope (Olympus, IX-70) and superfused (∼1 mL/min at 25°C) with a buffer containing (in mM): 131 NaCl, 4 KCl, 1 CaCl 2 , 1 MgCl 2 , 10 glucose, 10 HEPES, at pH 7.4. The cells were field stimulated to contract at 0.5 Hz, with a pair of platinum wires placed on opposite sides of the chamber connected to an FHC stimulator (Brunswick, NE). Myocytes were displayed on the computer monitor using an IonOptix MyoCam camera, which rapidly scans the image area every 8.3 milliseconds. The softedge software (IonOptix) was used to capture changes in cell length during shortening and relengthening. Only rod-shaped myocytes with clear edges were selected for recording.
Intracellular Ca 2+ Fluorescence Measurement
A separate cohort of myocytes was loaded with fura-2/AM (0.5 µM) for 15 minutes and fluorescence measurements were recorded with a dual-excitation fluorescence photomultiplier system (Ionoptix) as described. 18 Myocytes were placed in a chamber on the stage of an Olympus IX-70 inverted microscope and imaged through a Fluor 40x oil objective. Cells were exposed to light emitted by a 75W lamp and passed through either a 360 or a 380 nm filter (± 15 nm), while being stimulated to contract at 0.5 Hz. Fluorescence emissions were detected between 480 and 520 nm by a photomultiplier tube after first illuminating cells at 360 nm for 0.5 seconds then at 380 nm for the duration of the recording protocol (333 Hz sampling rate). The 360-nm excitation scan was repeated at the end of the protocol and qualitative changes in intracellular Ca 
␤-Galactosidase (X-Gal) Assay
The efficiency of adenoviral gene transfer was determined by X-Gal staining (X-Gal staining assay kit, GTS Inc, CA). Myocytes transfected with adenovirus encoded with ␤-Galactosidase (␤-Gal) were washed twice with PBS and fixed with 1% glutaraldehyde in PBS for 15 minutes at room temperature. The fixative was removed by 2 wash steps with PBS and cells were stained in X-Gal staining solution for 8 hours at 37°C. 16 
Western Blot Analysis for Expression of eNOS and iNOS and Akt Phosphorylation
Membrane proteins from control, eNOS, or LacZtreated myocytes after 36 hours viral gene transfer were extracted as described. 18 All myocytes from culture dishes were collected, sonicated, and the supernatants were centrifuged at 7000 × g for 30 minutes at 4°C. The pellets were cellular membrane fractions and were used for immunoblotting of eNOS, iNOS, Akt, and phosphorylated Akt (pAkt). We confirmed that these membrane fractions did not contain any detectable collagens. Membrane proteins (50 µg/lane) were separated on 10% (Akt and pAkt) or 7% (eNOS and iNOS) SDS-polyacrylamide gels in a mini-gel apparatus (Mini-PROTEAN II, Bio-Rad) and transferred to polyvinylidene diflouride membranes. The membranes were blocked (4% Block Ace, Dainippon Pharmaceutical, Osaka, Japan) and then incubated for 12 hours with anti-eNOS or anti-iNOS mouse IgG monoclonal antibodies (1:1000, BD Transduction Laboratories, Lexington, KY). The primary antibodies for Akt and pAkt were sheep/rabbit immunoaffinity purified IgG (1:1000, Upstate Biotechnology, Lake Placid, NY). Membranes were then washed and incubated with a horseradish peroxidase-conjugated anti-mouse (eNOS and iNOS), anti-rabbit (pAkt), or anti-sheep (Akt) IgG (1:5000 dilution) for 1.5 hours. After immunoblotting, the film was scanned and the intensity of immunoblot bands was detected with a Bio-Rad Calibrated Densitometer (Model: GS-800).
Nitric Oxide Synthase Activity Assay
Nitric oxide synthase (NOS) activity was evaluated by the 3 H-arginine to 3 H-citrulline conversion assay. 20 Briefly, plated ventricular myocytes (about 300,000/well) were placed in Hanks Balanced Salt Solution (HBSS) medium (20 mM HEPES, 1% penicillin-streptomycin, 0.1% BSA) for 20 minutes at 37°C before being replaced with HBSS containing 1 µCi/ml 3 H-arginine (Amersham Pharmacia Biotech, Inc., Piscataway, NJ) with Trasylol (0.2 KIU/ml) and leptin. The cells were then incubated for 60 minutes before the reaction was terminated by aspiration of the incubation medium and replacement with iced, HBSS containing 5 mM L-arginine and 4 mM EDTA. Five minutes later, the termination medium was removed and cells were lysed with 20 mM TRIS (with 5 mM L-arginine and 4 mM EDTA). Following sonication, the total lysate was centrifuged (600 g, 4°C, 10 minutes). An aliquot of the supernatant was diluted with 1:1 (vol/vol) H 2 O/Dowex-50W (20-50, 8% crosslinked), mixed vigorously, and loaded on a polypropylene EconoColumn (BioRad Laboratories, Inc., Hercules, CA). The gel bed was washed 3 times with 2 mL of distilled water and all effluent was collected.
3 H-citrulline was counted by scintillation.
Statistical Analyses
For each experimental series, data are presented as mean ± SEM. Statistical significance (P < 0.05) for each variable was estimated by analysis of variance (ANOVA) or t test, where appropriate (SYSTAT, Inc., Evanston, IL).
RESULTS
X-Gal Staining, eNOS Expression, and Nitric Oxide Synthase Activity in Ventricular Myocytes
The transfection efficacy of the adenoviral vector on isolated adult rat ventricular myocytes was evaluated using X-Gal staining of the adenoviral-LacZ construct carrying the ␤-Gal gene. As evidenced by the X-Gal staining, approximately 40% to 50% of the cardiac myocytes were successfully transduced at a MOI of 50 pfu/myocytes (Fig.1) . Western blot analysis showed that the expression of eNOS was significantly enhanced in the ventricular myocytes transfected with eNOS but not ␤-Gal (LacZ) or control after 36 hours (Fig. 2) . Consistently, the increase in eNOS protein abundance was associated with enhanced NOS activity in myocytes transduced with eNOS but not LacZ or groups (Fig. 2) . These results validated the eNOS viral gene transfer. In addition, the elevated eNOS protein abundance and NOS activity were paralleled with a FIGURE 1. X-Gal staining in cardiac myocytes transfected with adenovirus encoding ␤-galactosidase (␤-Gal). Myocytes were stained in X-Gal staining solution for 8 hours at 37°C.
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10% increase in the phosphorylation of the serine-threonine protein kinase B/Akt in eNOS transduced myocytes (P < 0.05 versus control). The total Akt level was not affected by eNOS gene transfer (Fig. 2) .
Effect of eNOS Gene Transfer on Myocyte Shortening and Relengthening
Adenoviral gene transfer did not significantly affect the overall appearance (shape and resting cell length, CL) of isolated myocytes over the duration of experimentation. As depicted in both the representative traces and pooled bar graph in Figure 3 , the eNOS-transduced myocytes displayed significantly enhanced peak shortening (PS, normalized to CL) at MOI of 50 and 100 (but not at 10 MOI) compared with that of the control group. The enhanced PS was associated with elevated maximal velocities of shortening/relengthening (± dL/dt) and comparable duration of shortening (TPS) and relengthening (TR 90 ) in eNOS-transduced myocytes. The marker gene ␤-Gal alone had no effect on PS, TPS, TR 90 , and ± dL/dt when compared with the myocytes from control group.
Effect of eNOS Gene Transfer on Intracellular Ca 2+ Transients
The membrane permeant fluorescent dye fura-2AM was used to evaluate the properties of intracellular Ca 2+ transients in myocytes from control, eNOS, and LacZ (␤-Gal) groups. The time course of the fluorescence signal decay was fitted into a single exponential equation, and the decay rate (tau) was used as an indicator of intracellular Ca 2+ clearing. The fluorescence measurements revealed that the resting intracellular Ca 2+ level was significantly elevated in eNOS-transduced myocytes (at MOI of 10, 50, and 100). The intracellular Ca 2+ rise in response to electrical stimulus (⌬FFI) was also enhanced in eNOS-transduced myocytes (at MOI of 50 and 100), consistent with the enhanced PS in eNOS-transduced myocytes. The intracellular Ca 2+ clearing indicated as intracellular Ca 2+ decay rate (tau) was not significantly affected by eNOS (Fig. 4) . These results revealed the mechanical effects of eNOS gene transfer on myocyte shortening may be underscored by its effect on intracellular Ca 2+ handling. The representative traces in Figure 4 were scaled to the same baseline value to better illustrate the effect of eNOS gene transfer on ⌬FFI. Myocyte shortening was also recorded from fura-2 loaded cells but was used for qualitative comparisons only, to avoid potential effects on contraction from intracellular Ca 2+ buffering by fura-2.
Effect of eNOS on Myocyte Shortening in the Presence of Phosphatidylinositol-3 (PI-3) Kinase Inhibitors
Phosphatidylinositol-3 (PI-3) kinase and PKB/Akt have been suggested to be involved in the regulation of NO signaling. 21, 22 To elucidate the mechanism of action in eNOSinduced cardiac mechanical response and the possible involvement of PI-3 kinase in eNOS gene transfer-induced cardiac response, myocytes were transduced with eNOS or ␤-Gal adenovirus in the presence of selective inhibitors of PI-3 kinase wortmannin (100 nM) and LY294002 (50 µM). Consistent with our earlier observations eNOS, but not LacZ, enhanced the myocyte-shortening amplitude. However, the observation that this effect may be ablated by wortmannin or LY294002 suggests a role of PI-3 kinase in the eNOS gene transferelicited cardiac contractile response (Fig. 5) .
DISCUSSION
Our in vitro study demonstrated for the first time that eNOS gene transfer directly promotes cardiac mechanical response in isolated ventricular myocytes, validating an important modulatory role of NO and therapeutic potential in certain conditions where cardiac function may be compromised. Isolated cardiac myocytes were transduced with adenovirus vectors encoding ␤-galactosidase or eNOS gene. The efficacy of gene transfer was validated by the X-Gal staining, eNOS protein expression, and NOS activity measurements. The duration of eNOS gene transfer employed in our study was compatible with the previous reports using adenovirus vectors. 23 Although inflammation and cytotoxicity that resulted from adenovirus infection may be a potential factor affecting our present findings, 24 the fact that the replication-deficient adenovirus was not innately harmful to the mechanical function and intracel- eNOS Gene Transfer and Cardiac Contractile Function lular Ca 2+ homeostasis suggest that it was unlikely that alteration in cardiac contractile function due to eNOS gene transfer resulted from inflammation or cytotoxicity.
The most novel finding of our study is that eNOS gene transfer into isolated ventricular myocytes enhanced PS, ± dL/dt, baseline FFI, and ⌬FFI without affecting tau, TPS, and TR 90 . The observation that peak shortening amplitude (PS) and maximal velocity of shortening/relengthening are elevated following eNOS gene transfer is consistent with reports that NO may display a biphasic effect on cardiac voltagedependent Ca 2+ current and contractility, including potentiation at lower concentrations and attenuation at higher concentrations. 8, 25 Increase in NO has been shown to result in a concerted activation of the sarcoplasmic reticulum Ca 2+ channel, which may override NO-induced cGMP-mediated inhibition of the Ca 2+ channel. 26 In our study, duration of shortening (TPS) and relengthening (TR 90 ) was not affected by eNOS gene transfer, suggesting that intracellular Ca 2+ release and resequestration may not be affected by NO. This is consistent with the finding that intracellular Ca 2+ clearing was not altered by eNOS gene transfer. Results from our present study revealed that enhanced contractile function may be related to the improved intracellular Ca 2+ release in response to electrical stimuli (⌬FFI) following eNOS gene transfer. Nevertheless, the mechanism(s) of action responsible for this improved intracellular Ca 2+ recruitment remains to be studied. The observation that eNOS gene transfer increased resting intracellular Ca 2+ level (basal FFI) is not clear at this time but may be related to the enhanced sarcolemmal Ca 2+ channel activity in response to eNOS gene transfer. The discrepancy between basal FFI and ⌬FFI in response to eNOS (at 10 and 50 MOI) may be due to different mechanisms regulating intracellular Ca 2+ levels under resting (basal FFI) versus increase in intracellular Ca 2+ following excitation (⌬FFI). Overall, our current study may provide some clarification regarding the direct impact of NO on cardiac contractile function since previous reports have yielded somewhat conflicting results with regard to the modulatory role of NO in the cardiac function.
Additional information regarding the role of eNOS on cardiac contractile function has been provided recently in light of the genetic knockout eNOS−/− mice. 11, 27 Hearts from eNOS knockout mice exhibit a normal inotropic and lusitropic function with either decreased or unchanged heart rate, which do not favor the positive cardiac inotropic effect of eNOS seen in our current study. We suspect that the discrepancy between the eNOS knockout mice and our in vitro study may be largely due to the possible compensatory mechanisms such as upregulation of other NOS isoforms in the setting of whole animal. eNOS gene deletion (especially non-conditional) may produce certain phenotypical adaptations such as ventricular hypertrophy resulting from sustained hypertension, and therefore may confound the interpretation for any direct cardiac effect of eNOS. Nevertheless, the availability of eNOS−/− mice has undoubtedly enriched our understanding of the complex role of eNOS (or in conjunction with any other NOSs) in the regulation of cardiac function. On the other hand, our present investigation has limitations inherent to any in vitro study in that the precise fate of NO and its cellular interactions cannot be readily duplicated as the in vivo setting.
In this study, we demonstrated that the eNOS-induced cardiac contractile response may be mediated through a PI-3 kinase-dependent pathway and paralleled with a slight but significant increase in the phosphorylation of the serine/threonine PKB/Akt. Interestingly, both PI-3 kinase and PKB/Akt have been speculated to be upstream of the activation of eNOS and have been shown to be directly associated with positive cardiac inotropic actions. 17, 22 Inhibition of the PI-3 kinase or PKB/Akt pathway, or mutation of the Akt site on eNOS protein (at serine-1177 in human) has been shown to attenuate the serine phosphorylation and prevent eNOS phosphorylation. 21, 22 To the contrary, phosphorylation of the serine-1177 (or serine-1179 in bovine) sites on eNOS may also activate Akt in a retrograde fashion, which enhances the enzymatic sensitivity to Ca 2+ and phosphorylates eNOS itself, indicating that phosphorylation of eNOS and activation of PI-3/Akt may represent a novel "feed-forward" regulatory mechanism for activation of eNOS. 21, 22 It is not clear as to how phosphorylation of this C-terminal serine residue activates NOS, although it has been speculated that such serine phosphorylation may diminish the auto-inhibition of calmodulin binding. 28 Although direct linkage between Akt activation and cardiac contractile response is not fully clear, in vivo gene transfer of constitutively active Akt mutant dramatically improves cardiac function in a rat model of cardiac ischemia-reperfusion injury. 29 Such positive cardiac contractile effect is not simply originated from infarct size reduction but rather is due to direct functional enhancement of Akt. This is supported by the fact that dominant negative Akt, which blocks Akt activation, accelerates hypoxiainduced cardiomyocyte dysfunction and death. 29 The potential cardiac contractile effect of Akt may contribute to, at least in part, eNOS gene transfer-induced positive cardiac contractile responses observed in our current study although further study is warranted to elucidate the precise mechanism of action.
In summary, our study demonstrated that eNOS gene transfer into the isolated ventricular myocytes ex vivo improves cardiac contractile function and intracellular Ca 2+ handling. Transfection of replication-defective adenoviral vectors encoding cDNA of eNOS into the ventricular myocytes may provide a way to study the effects of increased NO production in the heart on the regulation of cardiac pump function. The major challenge now is to confirm the emerging paradigms of cardiac functional regulation from eNOS and quickly translate them into therapy. In fact, eNOS gene transfer has shown some promising clinical implications to improve or benefit the cardiac function in patients with congestion heart failure, myocar-dial ischemia/reperfusion injury, and coronary artery disease. 30, 31 
